Prognostic Significance of Lewis y Antigen in Resected Stage I and II Non-small Cell Lung Cancer: Results

There were 22 (8.6%) specimens with no staining in group 0, 29 (11.3%) in group 1 (1 to < 25%), 62 (24.1%) in group 2 (25 to < 50%), 89 (35%) in group 3 (50 to < 75%), and 54 (21%) in group 4 (75 to 100%). When no staining (group 0) was compared with cells with 75 to 100% staining (group 4) there was no significant difference in overall survival nor DFS. Moreover, when no staining (group 0) was compared with the rest of the cells with some staining (groups 1 through 4), there was again no difference in survival nor DFS (data not shown). Therefore, further analysis was done, using combined groups 0 through 2 vs combined groups 3 and 4, to provide relatively equal groups.
The median survival for patients with negative expression of Ley (< 50% of positive cells) was 46 months, whereas for those with positive Ley expression (> 50%) it was 54 months (Fig 2; p = 0.99). The DFS was 39 months for patients with negative Ley expression and 34 months for patients with positive Ley expression (Fig 3; p = 0.3).
We also analyzed Ley expression by stage: In stage I patients, the median survival was 50 months for those with Ley(~) expression and 55 months for Ley( + ) expression (p = 0.4). For stage II patients, the median survival was 24 months for those with Ley( —) and 32 months for Ley( + ) expression (p = 0.62) .
Data were also analyzed for association with other variables studied previously, including age, sex, mucin, symptoms, smoking, loss of antigen, percent of S-phase, histology, and proliferation (Ki-67 expression). The only variables statistically significantly associated with expression of Ley were ploidy and Ki-67 expression (Table 2). One hundred and thirty-one patients were aneuploid, and 72 of 131 (55%) had Ley( + ) expression (p = 0.02). Buy dexone online More info Of those with diploid tumors, 20 of 55 (36%) had Ley( + ) expression. The proliferative marker Ki-67 expression was inversely related with expression of Ley. Of the patients, 31% had decreased expression of Ki-67 (< 25%) and negative Ley, whereas 68% had decreased Ki-67 expression and positive Ley (p = 0.01, Table 2).

Figure 2. Overall survival for patients with positive (> 50%) and negative (< 50%) expression of Ley (p = 0.99).

Figure 2. Overall survival for patients with positive (> 50%) and negative (< 50%) expression of Ley (p = 0.99).

Figure 3. DFS for patients with positive 50%) and negative (< 50%) expression of Ley (p = 0.37).

Figure 3. DFS for patients with positive 50%) and negative (< 50%) expression of Ley (p = 0.37).

Table 2—Relationship Between Ley Expression and Other Prognostic Variables

Variable Overall (n) <50% Cells (n) > 50% Cells (n) PValue
Age, mo 64.32 (256) 64.83 (113) 63.91 (143) 0,57
Stage, %
All 100 (256) 44.1 (113) 55.9(143)
I 73.8 (189) 47.1 (89) 52.9(100) 0.11
II 26.2 (67) 35.8 (24) 64.2 (43)
Sex
M 70.7(181) 43 (78) 57(103) 0.60
F 29.3 (75) 47 (35) 53 (40)
T Stage
I 34.0 (87) 47.1 (41) 52.9 (46) 0.49
II 66.0(177) 45.2 (80) 54.8 (97)
Mucin
+ 30.9 (79) 41.8 (33) 58.2 (46) 0.61
69.1 (177) 45.2 (80) 54.8 (97)
Squamous 28.6 (72) 48.6 (35) 51.4 (37) 0.40
cell
Nonsquamous 71.4(180) 42.8 (77) 57.2 (103)
Symptoms
+ 62.3 (157) 48.4 (76) 51.6 (81) 0.10
37.3 (95) 37.9 (36) 62.1 (59)
Ki-67
< 25% 23.8 (48) 31.3(15) 68.8 (33) 0.01*
> 25% 76.2 (154) 51.9 (80) 48.1 (74)
Cough
+ 40.3 (102) 48.0 (49) 52.0 (53) 0.32
59.7 (151) 41.7(63) 58.3 (88)
Antigen A
+ 59.6 (53) 49.1 (26) 50.9 (27) 0.87
40.4 (36) 47.2 (17) 52.8 (19)
Diploid 29.6 (55) 63.6 (35) 36.4 (20) 0.02*
Aneuploid 70.4 (131) 45.0 (59) 55.0 (72)
S-phase
> 8% 29.3 (44) 32.5 (25) 26.0 (19) 0.39
s 8% 70.7 (106) 67.5 (52) 74.0 (54)